“My passion is helping clients find the smartest path to bring innovative FDA-regulated products to market—and keep them compliant and competitive. Drawing on deep regulatory expertise and practical industry experience, I guide clients through complex challenges to support lasting business success.”
Michael R. Goodman
Principal Attorney
- Washington, DC
- mgoodman@ofwlaw.com
- (202) 518-6378
Michael Goodman is a nationally recognized attorney and registered patent agent who advises clients on complex regulatory, transactional, and dispute matters in the FDA-regulated space. With nearly 20 years of combined industry and legal experience, Michael counsels startups and established multinational companies on the best, most efficient routes to bring regulated products to market and stay compliant.
His practice encompasses the full lifecycle of FDA-regulated products, including prescription and OTC drugs, medical devices, dietary supplements, cosmetics, and conventional foods. He is also a recognized expert in advising on kashrut-related food manufacturing issues. Michael regularly assists clients with regulatory strategy, product labeling and advertising review, health authority enforcement actions, and large-scale product recalls.
Before joining OFW, Michael served as in-house regulatory and GMP counsel at one of the world’s largest pharmaceutical companies, where he guided global quality and regulatory teams through inspections, enforcement actions, major recalls, and health authority responses. Earlier in his career, Michael practiced at two Am Law 100 law firms, handling high-stakes FDA regulatory, enforcement, advertising, and product liability matters for major pharmaceutical, medical device, biotech, and dietary supplement companies.
He routinely advises on regulatory strategy, labeling and advertising compliance and claim substantiation, enforcement defense, product recalls, and negotiation of supply, manufacturing, and distribution agreements. Michael also regularly handles FDA regulatory diligence in mergers, acquisitions, private equity transactions, and public company filings.
Representative matters include:
- Leading the FDA regulatory diligence on a $1.25 billion acquisition of a national orthotics and prosthetics company.
- Serving as lead regulatory counsel on a $3.3 billion biosimilar portfolio divestment for a global pharmaceutical company.
- Advising a national wellness company with over 200 locations offering services including cryotherapy, red light therapy, infrared sauna sessions, compression therapy, IV therapy, and intramuscular injections.
- Representing a private equity firm targeting distressed companies for asset acquisitions, primarily in the women’s health sector.
- Guiding a global pharmaceutical company through a consent decree and numerous FDA-regulated companies in responding to FDA Form 483 observations and Warning Letters.
- Defending a national grocery store chain in lawsuits alleging false and misleading advertising.
- Assisting a biopharmaceutical company during one of the largest product recalls in U.S. history.
- Advising countless food and dietary supplement companies on labeling, advertising, and marketing compliance with federal and state regulations.
- Representing a major can manufacturer in a cross-border commercial dispute involving spoiled food products.
Credentials
Education
- J.D., University of Denver Sturm College of Law
- M.S., Biotechnology, University of Wisconsin–Madison School of Medicine and Public Health
- B.S., Biochemistry, University of Wisconsin–Madison
Bar/Court Admissions
- Colorado Bar
- District of Columbia Bar
- United States Patent and Trademark Office (Reg. No. 72223)
Leadership & Community
Michael currently serves on the Board of Directors for both the Denver Tennis Club and his synagogue. A proud former NCAA Division I student-athlete, he played on the University of Wisconsin–Madison’s varsity men’s tennis team (the Badgers) and remains actively involved in community youth sports programs.
News & Insights
Small Businesses Face Reporting Obligations Under The U.S. Corporate Transparency Act
Beginning January 1, 2024, the U.S. Corporate Transparency Act (CTA) will expect a wide range of small companies to begin filing reports identifying “beneficial owners.”
How will FDA and USDA operate during a Government Shutdown?
Will we wake up to a federal government shutdown on October 1st? Many of the ingredients required for a shutdown are present. There may be
Dillard to Provide Webinar on USDA Meat and Poultry Labeling Requirements
OFW Law’s USDA Practice Head, John Dillard, will be providing a free webinar on USDA Food Safety Inspection Service (FSIS) regulatory requirements for labeling meat and